Innovation-Driven Pharma Firm Eyes Long-Term Growth

Rubicon Research Ltd. (RRL), incorporated in 1999, is a pharmaceutical formulations company driven by innovation and focused R&D. With a growing portfolio of specialty products and drug-device combinations targeting regulated markets — particularly the United States — RRL continues to strengthen its global footprint. The upcoming issue comprises a fresh issue of ₹500 crore and an offer for sale (OFS) worth ₹877.50 crore. Notably, the company will not receive any proceeds from the OFS. Of the fresh issue proceeds, ₹310 crore will be utilized to prepay or repay existing borrowings, while the balance will be used for general corporate purposes. Valuation & Outlook: At a P/E of 52.5x (TTM EPS ₹9.2) and an EV/Sales of 6.1x, Rubicon Research commands a valuation premium versus industry peers. This is justified by its robust brand equity, expanding high-growth B2B portfolio, and consistent operational performance. Supported by strategic initiatives and positive sector tailwinds, RRL is well-positioned for sustainable long-term growth. ✅ Recommendation: Subscribe for Long Term #RubiconResearchIPO #PharmaInnovation #IndianMarkets #StockMarketIndia #InvestmentOpportunity #HealthcareSector #LongTermGrowth